An IL-12/Shh-C domain fusion protein-based IL-12 autocrine loop for sustained natural killer cell activation

International Journal of Oncology

Volumn 41, Issue 2, 2012, Pages 661-669

  Zhu, Lining ^a   Zhao, Zhihui ^b   Wei, Yanzhang ^a   Marcotte, William ^a   Wagner, Thomas E ^c   Yu, Xianzhong ^a  

^a CLEMSON UNIVERSITY   (United States)

^b JILIN UNIVERSITY   (China)

^c Orbis Health Solutions   (United States)

Author keywords

Activation; Autocrine; Fusion; Interleukin 12; Natural killer cells; Sonic hedgehog C terminal domain

Indexed keywords

CHOLESTEROL; ENHANCED GREEN FLUORESCENT PROTEIN; GAMMA INTERFERON; HYBRID PROTEIN; INTERLEUKIN 12 SONIC HEDGEHOG C TERMINAL DOMAIN FUSION PROTEIN; LENTIVIRUS VECTOR; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; CELL ACTIVATION; CELL INFILTRATION; CELL PROLIFERATION; CHEMICAL MODIFICATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; FUSION GENE; IMMUNOFLUORESCENCE TEST; LUNG PARENCHYMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SUPERNATANT; SURVIVAL TIME;

EID: 84863571366     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1466     Document Type: Article

References (32)

1. Moretta A, Bottino C, Mingari MC, Biassoni R and Moretta L: What is a natural killer cell? Nat Immunol 3: 6-8, 2002. (Pubitemid 34065607)
2. Smyth MJ, Thia KY, Cretney E, et al: Perforin is a major contributor to NK cell control of tumor metastasis. J Immunol 162: 6658-6662, 1999. (Pubitemid 29309390)
3. Lauwerys BR, Garot N, Renauld JC, and Houssiau FA: Cytokine production and killer activity of NK/T-NK cells derived with IL-2, IL-15, or the combination of IL-12 and IL-18. J Immunol 165: 1847-1853, 2000. (Pubitemid 30643135)
4. Smith BR, Rosenthal DS and Ault KA: Natural killer lymphocytes in hairy cell leukemia: presence of phenotypically identifiable cells with defective functional activity. Exp Hematol 13: 189-193, 1985. (Pubitemid 15040362)
5. Biron CA, Nguyen KB, Pien GC, Cousens LP and Salazar- Mather TP: Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 17:189-220, 1999.
6. Rosenberg S: Lymphokine-activated killer cells: a new approach to immunotherapy of cancer. J Natl Cancer Inst 75: 595-603, 1985.
7. Trinchieri G, Matsumoto-Kobayashi M, Clark SC, Seehra J, London L and Perussia B: Response of resting human peripheral blood natural killer cells to interleukin 2. J Exp Med 160: 1147-1169, 1984. (Pubitemid 14020973)
8. Goding SR, Yang Q, Knudsen KB, Potter DM and Basse PH: Cytokine gene therapy using adenovirally transduced, tumor-seeking activated natural killer cells. Hum Gene Ther 18: 701-711, 2007. (Pubitemid 47378067)
9. Rosenberg SA, Lotze MT, Muul LM, et al: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313: 1485-1492, 1985. (Pubitemid 16212345)
10. Yang Q, Hokland ME, Bryant JL, et al: Tumor-localization by adoptively transferred, interleukin-2-activated NK cells leads to destruction of well-established lung metastases. Int J Cancer 105: 512-519, 2003. (Pubitemid 36578556)
11. Loza MJ and Perussia B: The IL-12 signature: NK cell terminal CD56+high stage and effector functions. J Immunol 172: 88-96, 2004. (Pubitemid 38020459)
12. Maas RA, Dullens HF and Den Otter W: Interleukin-2 in cancer treatment: disappointing or (still) promising? A review. Cancer Immunol Immunother 36: 141-148, 1993. (Pubitemid 23047711)
13. Imboden M, Shi F, Pugh TD, et al: Safety of interleukin-12 gene therapy against cancer: a murine biodistribution and toxicity study. Hum Gene Ther 14: 1037-1048, 2003. (Pubitemid 36851396)
14. Ji J, Li J, Holmes LM, et al: Glycoinositol phospholipid-anchored interleukin 2 but not secreted interleukin 2 inhibits melanoma yumor growth in mice. Mol Cancer Ther 1: 1019-1024, 2002.
15. Konstantinidis KV, Alici E, Aints A, Christensson B, Ljunggren HG and Dilber MS: Targeting IL-2 to the endoplasmic reticulum confines autocrine growth stimulation to NK-92 cells. Exp Hematol 33 :159-164, 2005. (Pubitemid 40164897)
16. Gurdon JB and Bourillot PY: Morphogen gradient interpretation. Nature 413: 797-803, 2001. (Pubitemid 33026841)
17. Cadigan KM: Regulating morphogen gradients in the Drosophila wing. Semin Cell Dev Biol 13: 83-90, 2002.
18. Lawrence PA and Struhl G: Morphogens, compartments, and pattern: lessons from Drosophila? Cell 85: 951-961, 1996.
19. Tabata T and Kornberg TB: Hedgehog is a signaling protein with a key role in patterning Drosophila imaginal discs. Cell 76: 89-102, 1994.
20. Teleman AA, Strigini M and Cohen SM: Shaping morphogen gradients. Cell 105: 559-562, 2001. (Pubitemid 32524107)
21. Vincent JP and Dubois L: Morphogen transport along epithelia, an integrated trafficking problem. Dev Cell 3: 615-623, 2002.
22. Mann RK and Beachy PA: Novel lipid modifications of secreted protein signals. Annu Rev Biochem 73: 891-923, 2004. (Pubitemid 39050389)
23. Guerrero I and Chiang C: A conserved mechanism of Hedgehog gradient formation by lipid modifications. Trends Cell Biol 17: 1-5, 2007. (Pubitemid 46027586)
24. Vincent S, Thomas A, Brasher B and Benson JD: Targeting of proteins to membranes through hedgehog auto-processing. Nat Biotechnol 21: 936-940, 2003. (Pubitemid 36936202)
25. Sanda MG, Restifo NP, Walsh JC, et al: Molecular characterization of defective antigen processing in human prostate cancer. J Natl Cancer Inst 87: 280-285, 1995.
26. Robertson MJ and Ritz J: Biology and clinical relevance of human natural killer cells. Blood 76: 2421-2438, 1990.
27. Albertsson PA, Basse PH, Hokland M, et al: NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity. Trends Immunol 24: 603-609, 2003. (Pubitemid 37338529)
28. Basse PH, Whiteside TL and Herberman RB: Cancer immunotherapy with interleukin-2-activated natural killer cells. Mol Biotechnol 21: 161-170, 2002. (Pubitemid 34521614)
29. Law TM, Motzer RJ, Mazumdar M, et al: Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 76: 824-832, 1995.
30. Kammula US, White DE and Rosenberg SA: Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer 83: 797-805, 1998. (Pubitemid 28387707)
31. Herberman RB, Reynolds CW and Ortaldo JR: Mechanism of cytotoxicity by natural Killer (NK) cells. Annu Rev Immunol 4: 651-680, 1986.
32. Skoskiewicz MJ, Colvin RB, Schneeberger EE and Russell PS: Widespread and selective induction of major histocompatibility complex-determined antigens in vivo by gamma interferon. J Exp Med 162: 1645-1664, 1985. (Pubitemid 16195365)